| Title |
Towards Clinical Application of Mesenchymal Stem Cells for Treatment of Neurological Diseases of the Central Nervous System
|
|---|---|
| Published in |
Journal of Neuroimmune Pharmacology, April 2013
|
| DOI | 10.1007/s11481-013-9456-6 |
| Pubmed ID | |
| Authors |
Alice Laroni, Giovanni Novi, Nicole Kerlero de Rosbo, Antonio Uccelli |
| Abstract |
The diagnosis of a neurological disease of the central nervous system (CNS) is often associated with the anticipation of an irreversible and untreatable disability. This is the case also of multiple sclerosis (MS) where approved treatments effectively modulate the autoimmune attack to myelin antigens, but poorly affect neurodegeneration and do not promote tissue repair. Thus, stem cell-based therapies are increasingly being considered a possible strategy for diseases of the CNS. Mesenchymal stem cells (MSC), the safety of which has been demonstrated in the last 20 years through clinical trials and case studies, are of particular interest in view not only of their neuroprotective, but also of their immunomodulatory properties. Here, we review the therapeutic features of MSC that make them relevant in the treatment of CNS illnesses and discuss the pioneer clinical experience with MSC-based therapy in neurological diseases. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Italy | 1 | 1% |
| South Africa | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 69 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 15% |
| Student > Master | 8 | 11% |
| Researcher | 7 | 10% |
| Student > Bachelor | 6 | 8% |
| Professor | 6 | 8% |
| Other | 16 | 22% |
| Unknown | 19 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 19 | 26% |
| Medicine and Dentistry | 18 | 25% |
| Neuroscience | 5 | 7% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Computer Science | 1 | 1% |
| Other | 6 | 8% |
| Unknown | 20 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2013.
All research outputs
#15,270,937
of 24,217,893 outputs
Outputs from Journal of Neuroimmune Pharmacology
#351
of 583 outputs
Outputs of similar age
#117,469
of 202,103 outputs
Outputs of similar age from Journal of Neuroimmune Pharmacology
#16
of 19 outputs
Altmetric has tracked 24,217,893 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 583 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,103 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.